Media stories about Danaher (NYSE:DHR) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Danaher earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned media coverage about the conglomerate an impact score of 46.3306782179711 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- $4.95 Billion in Sales Expected for Danaher Co. (DHR) This Quarter (americanbankingnews.com)
- Danaher to Present at J.P. Morgan Healthcare Conference (finance.yahoo.com)
- Brokerages Anticipate Danaher Co. (DHR) Will Announce Earnings of $1.15 Per Share (americanbankingnews.com)
- Danaher Corp. : DHR-US: Dividend Analysis : December 29th, 2017 (record date) : By the numbers : January 1, 2018 (finance.yahoo.com)
- Danaher Corp. breached its 50 day moving average in a Bearish Manner : DHR-US : January 1, 2018 (finance.yahoo.com)
Danaher (NYSE:DHR) traded up $1.23 during trading on Wednesday, reaching $93.67. The company’s stock had a trading volume of 2,474,514 shares, compared to its average volume of 3,049,150. Danaher has a 52 week low of $78.65 and a 52 week high of $95.16. The company has a quick ratio of 1.00, a current ratio of 1.43 and a debt-to-equity ratio of 0.42. The firm has a market cap of $65,160.00, a PE ratio of 27.88, a price-to-earnings-growth ratio of 2.02 and a beta of 1.03.
The firm also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be issued a $0.14 dividend. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $0.56 annualized dividend and a dividend yield of 0.60%. Danaher’s dividend payout ratio is currently 16.67%.
A number of research analysts recently issued reports on DHR shares. Robert W. Baird restated a “buy” rating and set a $99.00 price target on shares of Danaher in a research note on Friday, December 15th. Citigroup raised their price target on Danaher to $107.00 and gave the stock a “buy” rating in a research note on Friday, December 15th. Zacks Investment Research upgraded Danaher from a “hold” rating to a “buy” rating and set a $97.00 price target on the stock in a research note on Thursday, October 5th. Cowen restated a “buy” rating and set a $90.00 price target on shares of Danaher in a research note on Wednesday, October 4th. Finally, Credit Suisse Group reaffirmed a “hold” rating and set a $99.00 price objective on shares of Danaher in a research report on Tuesday, December 19th. One analyst has rated the stock with a sell rating, six have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $94.38.
In other news, Director Donald J. Ehrlich sold 10,578 shares of the firm’s stock in a transaction that occurred on Tuesday, October 24th. The stock was sold at an average price of $90.82, for a total value of $960,693.96. Following the completion of the sale, the director now directly owns 104,621 shares of the company’s stock, valued at approximately $9,501,679.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $92.64, for a total value of $11,671,620.96. Following the completion of the sale, the chief executive officer now directly owns 271,737 shares of the company’s stock, valued at $25,173,715.68. The disclosure for this sale can be found here. Insiders sold a total of 273,810 shares of company stock valued at $25,218,813 over the last three months. Insiders own 12.20% of the company’s stock.
WARNING: This article was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.com-unik.info/2018/01/03/danaher-dhr-getting-somewhat-favorable-news-coverage-study-shows.html.
Danaher Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.